Retrieve all available abstracts of the following 263 articles: HTML format
Single Articles
WANG Q, Xu W, Ying L, Shi H, et al Erratum: Preliminary study of the mechanism of isolinderalactone inhibiting the
malignant behavior of bladder cancer: Erratum.
Curr Urol. 2025;19:144. PubMed Abstract available
WANG Q, Xu W, Ying L, Shi H, et al Preliminary study of the mechanism of isolinderalactone inhibiting the malignant
behavior of bladder cancer.
Curr Urol. 2025;19:49-58. PubMed Abstract available
O'SULLIVAN NJ, Temperley HC, Corr A, Meaney JFM, et al Current role of radiomics and radiogenomics in predicting oncological outcomes in
bladder cancer.
Curr Urol. 2025;19:43-48. PubMed Abstract available
ZHENG CM, Kang HW, Moon S, Byun YJ, et al Optimizing extraction of microbial DNA from urine: Advancing urinary microbiome
research in bladder cancer.
Investig Clin Urol. 2025;66:272-280. PubMed Abstract available
SAHIN G, Gemalmaz H, Gok M Correlation of shear wave elastography with histopathological grade, tumor stage,
and microvessel density in bladder cancer.
Investig Clin Urol. 2025;66:207-214. PubMed Abstract available
LIU M, Zhang J, Zhu S, Jiang W, et al a1,3-mannosyltransferase promotes the malignant progression of bladder cancer
through activating TNF signaling pathway.
Eur J Med Res. 2025;30:353. PubMed Abstract available
JIN H, Wu P, Lv C, Zhang S, et al Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and
activate antitumor immune responses.
Commun Biol. 2025;8:689. PubMed Abstract available
CAI F, Xu S, Li Y, He Q, et al The role of the LncRNA XIST/miR-15a-5p/MN1 signaling axis in gender disparities
in bladder cancer prognosis.
Front Immunol. 2025;16:1554829. PubMed Abstract available
POPLI S, Durant AM, Tyson M, Singh P, et al Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder
Cancer and Localized Muscle Invasive Bladder Cancer.
Curr Oncol Rep. 2025 Apr 30. doi: 10.1007/s11912-025-01657. PubMed Abstract available
KASPERCZYK E, Tarhonska K, Jablonska E Epigenetic changes induced by carcinogenic agents or occupational exposure with
sufficient evidence for bladder cancer.
Cancer Prev Res (Phila). 2025 Apr 30. doi: 10.1158/1940-6207.CAPR-24-0450. PubMed Abstract available
YUAN Y, Chu G, Ma Q, Liang Z, et al Multiscale screening and identifying specific targets for artesunate in
suppressing bladder cancer.
Front Pharmacol. 2025;16:1584502. PubMed Abstract available
HO CY, Hwang TI, Peng PW, Tsai TF, et al Antitumor Effects of Sesamin via the LincRNA-p21/STAT3 Axis in Human Bladder
Cancer: Inhibition of Metastatic Progression and Enhanced Chemosensitivity.
Int J Biol Sci. 2025;21:2692-2706. PubMed Abstract available
TONG Z, Fu G, Zhou F, Liu X, et al Neoadjuvant Sintilimab Combined with Gemcitabine and Cisplatin (GP) for
Muscle-Invasive Bladder Cancer (MIBC) Patients Followed by Selective Bladder
Sparing Surgery: A Phase 2 Trial.
Cancer Res Treat. 2025 Apr 28. doi: 10.4143/crt.2025. PubMed Abstract available
KAWADA T, Kobayashi Y, Tsugawa T, Tsuboi K, et al Clinical Outcomes of Neoadjuvant Paclitaxel/Cisplatin/Gemcitabine Compared with
Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer.
Acta Med Okayama. 2025;79:81-92. PubMed Abstract available
HATAKEYAMA S, Taoka R, Miki J, Saito R, et al Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy
on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical
Cystectomy.
Cancer Med. 2025;14:e70782. PubMed Abstract available
BIDI SR, Ghagane SC, Rangrez S, Nerli R, et al Association of rs2294008 (PSCA) Gene polymorphism in Urothelial Bladder Cancer of
South Indian Population.
Asian Pac J Cancer Prev. 2025;26:1441-1446. PubMed Abstract available
YANG X, Wu X, Hao X, Li T, et al Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on
bladder cancer.
J Transl Med. 2025;23:489. PubMed Abstract available
SONG Z, Gui S, Rao X, Zhang G, et al TAZ/NRF2 positive feedback loop contributes to proliferation in bladder cancer
through antagonistic ferroptosis.
Cell Death Discov. 2025;11:208. PubMed Abstract available
SHEN CH, Wu JY, Wang SC, Liu HT, et al Enhanced tumor suppressive effect of a new HDAC inhibitor in bladder cancer in
vitro and in vivo.
Biomed Pharmacother. 2025;187:118108. PubMed Abstract available
SHEN Y, Wu Y, Yan C, Bi C, et al Nanobody-based double antibody sandwich colloidal gold test strips for rapid
detection of urinary biomarkers NMP22 and survivin in bladder cancer.
J Pharm Biomed Anal. 2025;263:116905. PubMed Abstract available
KWEK SS, Yang H, Li T, Ilano A, et al Identification and regulation of circulating tumor TCR-matched cytotoxic CD4+
lymphocytes by KLRG1 in bladder cancer.
JCI Insight. 2025 Apr 29:e177373. doi: 10.1172/jci.insight.177373. PubMed Abstract available
KATAYAMA Y, Akioka T, Kimura S, Fujii M, et al Engineered Expression of Hepatocyte Growth Factor Activator Inhibitor-1 (HAI-1)
Reduces the Growth of Bladder Cancer Cells.
Biomedicines. 2025;13:871. PubMed Abstract available
UHLIG A [Secondary bladder cancer following radiation therapy for prostate cancer:
a systematic review and meta-analysis of incidence and outcomes].
Urologie. 2025 Apr 29. doi: 10.1007/s00120-025-02592. PubMed
TONIN E, Bianchi L, Mottaran A, Bronimann S, et al Radical cystectomy for bladder cancer in solid organ transplant recipients.
Minerva Urol Nephrol. 2025;77:202-208. PubMed Abstract available
LEONARDI R, Mantica G, Ambrosini F, Calarco A, et al The current status of biomarkers for bladder cancer: progress and challenges.
Minerva Urol Nephrol. 2025;77:149-151. PubMed
KLEEBAYOON A, Wiwanitkit V Change in the Neutrophil-Lymphocyte Ratio and Recurrence in Operated Bladder
Cancer.
Asia Pac J Clin Oncol. 2025 Apr 29. doi: 10.1111/ajco.14183. PubMed
CHEN S, Cheng J, Liu S, Shan D, et al Urinary exosomal lnc-TAF12-2:1 promotes bladder cancer progression through the
miR-7847-3p/ASB12 regulatory axis.
Genes Dis. 2024;12:101384. PubMed Abstract available
YANAGISAWA T, Matsukawa A, Teoh JY, Mori K, et al Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic
review from the beginning to the latest updates.
Bladder Cancer. 2025;11:23523735251335122. PubMed Abstract available
ZHAO H, Ho VWS, Liu K, Chen X, et al Organoid models in bladder cancer: From bench to bedside?
Bladder Cancer. 2025;11:23523735251330404. PubMed Abstract available
LIU M, Jia G, Meng X, Rong Y, et al Cyclic Enrichment of Urinary Exosomes Using a MOF-on-MOF-Based Asymmetric
Impinging Streams Chip for Bladder Cancer Diagnosis and Prognosis Prediction.
Adv Healthc Mater. 2025 Apr 28:e2500848. doi: 10.1002/adhm.202500848. PubMed Abstract available
LU Y, Li J, Qin X Study on extended-spectrum beta-lactamases genes and drug resistance in patients
with urinary tract infection of enterohemorrhagic Escherichia coli after bladder
cancer surgery.
Medicine (Baltimore). 2025;104:e42098. PubMed Abstract available
LI Y, Song X, Sun R, Dong X, et al [A pan-cancer analysis of PYCR1 and its predictive value for chemotherapy and
immunotherapy responses in bladder cancer].
Nan Fang Yi Ke Da Xue Xue Bao. 2025;45:880-892. PubMed Abstract available
ERAKY A, Hug B, Ben-David R, Kolanukuduru KP, et al Efficacy of Bacillus Calmette-Guerin compared to sequential gemcitabine and
docetaxel in Ta high-grade non-muscle invasive bladder cancer.
World J Urol. 2025;43:255. PubMed Abstract available
TRIPATHY R, Kumar L, Kural S, Thakur A, et al The current status of miRNA in urinary bladder cancer: A minireview and strength,
weakness, opportunity, and threat analysis.
Indian J Urol. 2025;41:98-103. PubMed Abstract available
AGRAWAL S Expanding horizons to cure muscle-invasive bladder cancer: A novel treatment
algorithm.
Indian J Urol. 2025;41:153-154. PubMed
PASCOAL LB, Jalalizadeh M, Barbosa G, da Silva ANMR, et al Viral infections and immune modulation in bladder cancer: implications for
immunotherapy.
Explor Target Antitumor Ther. 2025;6:1002311. PubMed Abstract available
VISAKH RA, Raja S, Pratap T, Thomas RM, et al Testicular Tuberculosis after Intravesical BCG for Urinary Bladder Cancer: A Role
of FDG PET-CT.
Indian J Nucl Med. 2024;39:460-462. PubMed Abstract available
MATSUKAWA A, Cormio A, Miszczyk M, Parizi MK, et al Impact of Immune Checkpoint Inhibitors as Neoadjuvant Therapy for Muscle-invasive
Bladder Cancer: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Eur Urol Oncol. 2025 Apr 26:S2588-9311(25)00043. PubMed Abstract available
SARKEES E, Taha F, Oudahmane I, Vuiblet V, et al Evaluation of the diagnostic potential of Fourier transform-infrared spectroscopy
on urine for urothelial bladder cancer: an in-hospital field study.
Spectrochim Acta A Mol Biomol Spectrosc. 2025;339:126274. PubMed Abstract available
GAO W Current laser application in En bloc resection of bladder tumor- a narrative
literature review.
World J Surg Oncol. 2025;23:165. PubMed Abstract available
TURDO A, Tulone G, Di Bella S, Porcelli G, et al Heightened IDO1 levels predict Bacillus Calmette-Guerin failure in high-risk
non-muscle-invasive bladder cancer patients.
Cell Death Discov. 2025;11:203. PubMed Abstract available
PACKIAM VT, McElree IM, Ghodoussipour S, Nimgaonkar V, et al Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated
with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to
Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade
Non-muscle-invasive Bl
Eur Urol Oncol. 2025 Apr 25:S2588-9311(25)00100. PubMed Abstract available
NAITO Y, Inoue S, Tochigi K, Shamoto N, et al Significance of Body Surface Area Correction for Cisplatin Eligibility Based on
Renal Function of Patients With Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer. 2025 Mar 28:102339. doi: 10.1016/j.clgc.2025.102339. PubMed Abstract available
FRASLIN AM, Benhamou S, Lebret T, Radvanyi F, et al Incidence of Bladder Cancer, Healthcare Pathways, and Economic Burden: A
Real-World Observational Study From the French National Healthcare System
Database.
Clin Genitourin Cancer. 2025;23:102344. PubMed Abstract available
GUO J, Xiong S, Zhang X, Gong W, et al Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment
of Bladder Cancer.
Pharmaceuticals (Basel). 2025;18:511. PubMed Abstract available
YING L, Chen R, Guo R, Liang Y, et al Paeonol Suppresses Bladder Cancer Progression via Apoptotic Pathways: Insights
from In Vitro and In Vivo Studies.
Pharmaceuticals (Basel). 2025;18:472. PubMed Abstract available
LYDOM LN, Raffing R, Lauridsen SV, Egerod I, et al Perspectives on an Intensive Hospital-Based Smoking Cessation Intervention in
Relation to Transurethral Resection of the Bladder Tumour (TURBT): Interviews
with Patients, Relatives, and Clinicians.
Int J Environ Res Public Health. 2025;22:555. PubMed Abstract available
TARANTINO G, Imbimbo C, Ferro M, Bianchi R, et al Which Surrogate Marker of Insulin Resistance Among Those Proposed in the
Literature Better Predicts the Presence of Non-Metastatic Bladder Cancer?
J Clin Med. 2025;14:2636. PubMed Abstract available
KORAK T, Baloglu IH, Kasap M, Arisan ED, et al Proteomic and In Silico Analyses Highlight Complement System's Role in Bladder
Cancer Immune Regulation.
Medicina (Kaunas). 2025;61:735. PubMed Abstract available
OYAERT M, Van Praet C, Delrue C, Speeckaert MM, et al Novel Urinary Biomarkers for the Detection of Bladder Cancer.
Cancers (Basel). 2025;17:1283. PubMed Abstract available
KATSUMATA H, Koguchi D, Hirano S, Suzuki A, et al Association Between CKAP4 Expression and Poor Prognosis in Patients with Bladder
Cancer Treated with Radical Cystectomy.
Cancers (Basel). 2025;17:1278. PubMed Abstract available
HUANG J, Lo UG, Wu S, Wang B, et al Correction: The roles and mechanism of IFIT5 in bladder cancer
epithelial-mesenchymal transition and progression.
Cell Death Dis. 2025;16:339. PubMed
CHEN H, Na X, Hu P, Ma Q, et al WWP1 mediates the ubiquitination and degradation of HIPK3 in bladder cancer
cells.
J Biol Chem. 2025 Apr 23:108528. doi: 10.1016/j.jbc.2025.108528. PubMed Abstract available
RYU H, Lee S, Song SH, Lee H, et al Acidic urine as a prognostic factor after intravesical Bacillus Calmette-Guerin
induction therapy for nonmuscle-invasive bladder cancer.
World J Urol. 2025;43:247. PubMed Abstract available
GAO D, Yin J, Tie P, Liu Q, et al Bioinformatics analysis reveals CTSF suppresses tumor cell malignant phenotype
and CD8 + T cell exhaustion by downregulating Bcl- 2 protein in the
microenvironment of bladder cancer.
Naunyn Schmiedebergs Arch Pharmacol. 2025. PubMed Abstract available
SANDBERG M, Whitman W, Bissette R, Ross C, et al Pulsed Electromagnetic Field Therapy Alters the Genomic Profile of Bladder Cancer
Cell Line HT-1197.
J Pers Med. 2025;15:143. PubMed Abstract available
VAKHRUSHEVA O, Zhao F, Markowitsch SD, Slade KS, et al Artesunate Inhibits Metastatic Potential in Cisplatin-Resistant Bladder Cancer
Cells by Altering Integrins.
Cells. 2025;14:570. PubMed Abstract available
PORFYRIS O, Detopoulou P, Adamantidi T, Tsoupras A, et al Phytochemicals as Chemo-Preventive and Therapeutic Agents Against Bladder Cancer:
A Comprehensive Review.
Diseases. 2025;13:103. PubMed Abstract available
SONG B, Kim D, Ho JN, Le VH, et al Crizotinib Inhibits Viability, Migration, and Invasion by Suppressing the
c-Met/PI3K/Akt Pathway in the Three-Dimensional Bladder Cancer Spheroid Model.
Curr Oncol. 2025;32:236. PubMed Abstract available
SURA S, Bupathi M, Morris V, Conkling P, et al Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab
Maintenance in US Patients with Locally Advanced or Metastatic Urothelial
Carcinoma: The SPEAR Bladder-II Study.
Curr Oncol. 2025;32:187. PubMed Abstract available
WU R, Li D, Zhang S, Wang J, et al Comprehensive pan-cancer analysis identifies PLAG1 as a key regulator of tumor
immune microenvironment and prognostic biomarker.
Front Immunol. 2025;16:1572108. PubMed Abstract available
COHEN Z, Petrenko E, Barisaac AS, Abu-Zhayia ER, et al SLAYER: a computational framework for identifying synthetic lethal interactions
through integrated analysis of cancer dependencies.
NAR Genom Bioinform. 2025;7:lqaf052. PubMed Abstract available
LI W, Wei W, Yuan L, Zhang Y, et al Clinicopathological features analysis of Paraganglioma of urinary bladder: A
retrospective study.
Ann Diagn Pathol. 2025;77:152477. PubMed Abstract available
STERNSCHUSS M, Rosenberg JE Enfortumab vedotin and pembrolizumab: redefining the standard of care for
previously untreated advanced urothelial cancer.
Future Oncol. 2025;21:1333-1348. PubMed Abstract available
GUPTA S, Climent Duran MA, Sridhar SS, Powles T, et al Avelumab first-line maintenance for advanced urothelial carcinoma: long-term
outcomes from the JAVELIN Bladder 100 trial in older patients.
ESMO Open. 2025;10:104506. PubMed Abstract available
MATSUBARA N, Osawa T, Abe T, Oya M, et al FGFR2/3 Gene Alterations and Clinical Outcomes in Advanced/Metastatic Urothelial
Cancer in Japan: MONSTAR-SCREEN Database Study.
Cancer Sci. 2025;116:1424-1432. PubMed Abstract available
TANEDA Y, Urabe F, Uchida N, Kadena S, et al Clinical outcomes and treatment patterns of maintenance avelumab in locally
advanced or metastatic urothelial carcinoma: a multicenter collaborative study.
Jpn J Clin Oncol. 2025;55:522-530. PubMed Abstract available
PUENTE J, Pinto A, Mendez-Vidal MJ, Garcia Del Muro X, et al Real-world treatment patterns, survival outcomes, and health care resource
utilization for locally advanced or metastatic urothelial carcinoma in Spain.
Clin Transl Oncol. 2025;27:2232-2240. PubMed Abstract available
CHEN C, Fan G, Li P, Yang E, et al Comparative study on the efficacy of low-dose and full-dose BCG bladder perfusion
therapy.
Clin Transl Oncol. 2025;27:2174-2190. PubMed Abstract available
XIE X, Sang Y, Shou D Early Palliative Care in Advanced or Metastatic Bladder Cancer: A Retrospective
Study.
Arch Esp Urol. 2025;78:371-379. PubMed Abstract available
OUYANG W, Wang H, Zhao Z, Wang M, et al Light-Responsive Ru-Se Coordinated Nanoreactor Spatiotemporally Relieves Hypoxia
for Photodynamic Therapy of Bladder Cancer.
ACS Appl Mater Interfaces. 2025 May 9. doi: 10.1021/acsami.5c05133. PubMed Abstract available
SCHMITZ-DRAGER BJ, Bismarck E, Roghmann F, von Landenberg N, et al Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided
Versus Cystoscopy-based Surveillance in Patients with Low/Intermediate-risk
Bladder Cancer.
Eur Urol Oncol. 2025 May 7:S2588-9311(25)00115-4. doi: 10.1016/j.euo.2025. PubMed Abstract available
YANG X, Wang L, Lin P, Ning Y, et al Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment
of bladder cancer.
Eur J Med Chem. 2025;293:117710. PubMed Abstract available
HUANG W, Li L, Liang Y, Yang Q, et al ImmunoPET Imaging of Nectin4 Expression in Gastric and Bladder Cancer Using
[(64)Cu]Cu-NOTA-Padcev.
Mol Pharm. 2025 May 8. doi: 10.1021/acs.molpharmaceut.5c00469. PubMed Abstract available
HWANG MW, Aragon-Ching JB The role of perioperative immunotherapy with chemotherapy in muscle-invasive
bladder cancer (MIBC).
Chin Clin Oncol. 2025;14:26. PubMed
NORGAARD M, Mailhac A, Fagerlund K, Strunz-McKendry T, et al Treatment patterns in patients with locally advanced and metastatic bladder
cancer in Denmark 2015-2023 - an updated analysis.
Acta Oncol. 2025;64:630-632. PubMed
CHUNYU L, Tonglei Z, Xinyang P, Kangkang C, et al Efficacy and safety of robotic-assisted laparoscopic "one-step" radical
nephroureterectomy and bladder cuff excision.
World J Urol. 2025;43:280. PubMed Abstract available
ZHANG H, Li J Oxymatrine Inhibits PKM2-Mediated Glycolysis and Enhances Cisplatin Sensitivity
in Bladder Cancer.
Tohoku J Exp Med. 2025 May 8. doi: 10.1620/tjem.2025. PubMed
CHEN L, Liu Z BAP1-mediated ubiquitination inhibition and CAS6/AXL signaling activation in
bladder cancer progression.
Cytotechnology. 2025;77:95. PubMed Abstract available
YAN H, Ji X, Li B Advancing personalized, predictive, and preventive medicine in bladder cancer: a
multi-omics and machine learning approach for novel prognostic modeling, immune
profiling, and therapeutic target discovery.
Front Immunol. 2025;16:1572034. PubMed Abstract available
GUO X, Zhang Y, Liu Q, Xu M, et al Progress on liposome delivery systems in the treatment of bladder cancer.
RSC Adv. 2025;15:14315-14336. PubMed Abstract available
HAGGSTROM C, Hagberg O, Holmberg L, Hosseini A, et al Risk of upper urinary tract urothelial carcinoma after primary
non-muscle-invasive urinary bladder cancer: A nationwide population-based cohort
study.
BJUI Compass. 2025;6:e70021. PubMed Abstract available
GIANNAKODIMOS I, Ziogou A, Giannakodimos A, Tzelepis K, et al Neoadjuvant immunotherapy for muscle-invasive bladder cancer: a 2025 update.
Immunotherapy. 2025 May 6:1-9. doi: 10.1080/1750743X.2025.2501929. PubMed Abstract available
PIJPERS OM, Bosch SG, van Diepen DC, Zee JY, et al Intravesical gemcitabine and docetaxel in patients with recurrent high-grade
nonmuscle invasive bladder cancer-A prospective cohort study.
Urol Oncol. 2025 May 5:S1078-1439(25)00124-3. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
HU ZJ, Yang L Comment on: "A review and meta-analysis: comparing the efficacy of robot-assisted
and open radical cystectomy in elderly bladder cancer patients".
J Robot Surg. 2025;19:199. PubMed
CHEN Y, Fan G, Wu Y, Wang Y, et al Comparison of perioperative outcomes between extracorporeal and intracorporeal
urethral diversion in robot-assisted radical cystectomy: a meta-analysis and
systematic review.
J Robot Surg. 2025;19:200. PubMed Abstract available
WIHL J, Oskar Hagberg, Firas Aljabery, Truls Gardmark, et al Lower MeDiC score is associated with non-referral to multidisciplinary team
meeting discussion in bladder cancer patients: a nationwide and population-based
study.
Acta Oncol. 2025;64:616-622. PubMed Abstract available
JIANG X, Cai L, Cao Q, Liu P, et al The role of multiparametric MRI-based VI-RADS in predicting the need for a second
TURB.
World J Urol. 2025;43:271. PubMed Abstract available
HAHN O, Kubler H [Bladder sparing options for muscle invasive high risk bladder cancer].
Aktuelle Urol. 2025 May 5. doi: 10.1055/a-2586-5554. PubMed Abstract available
CHEN J, Zhao J, Zuo J, Fu Y, et al HDL cholesterol esters mediate the genetic link between sedentary behavior and
urological cancers: Insights from mediation and validation analyses.
Medicine (Baltimore). 2025;104:e42369. PubMed Abstract available
YANG JJ, Zhao H, Yan MM, Zheng X, et al Identification of drug combinations to reduce the risk of pioglitazone-related
bladder cancer using the FDA adverse event reporting system database.
Expert Opin Drug Saf. 2025 May 6:1-10. doi: 10.1080/14740338.2025.2492744. PubMed Abstract available
AKAKPO JY, Abbott E, Woolbright BL, Ramachandran A, et al 4-Methylpyrazole-mediated inhibition of Cytochrome P450 2E1 protects renal
epithelial cells, but not bladder cancer cells, from cisplatin toxicity.
Toxicol Sci. 2025 May 5:kfaf053. doi: 10.1093. PubMed Abstract available
AL-KOHLANY K, Al-Maleki A, Al-Shami M, Hussein H, et al Current status of management and outcomes of muscle-invasive bladder cancer in
Yemen: a retrospective observational study.
Arch Ital Urol Androl. 2025 May 5. doi: 10.4081/aiua.2025.13760. PubMed Abstract available
LA ROCCA R, Di Mauro E, Falcone A, Sicignano E, et al Analysis and adherence to guidelines of mobile health application for bladder
cancer, where are we?
Arch Ital Urol Androl. 2025 May 5. doi: 10.4081/aiua.2025.13455. PubMed Abstract available
LIU L, He JH, Xiao Y, Wei D, et al Prognostic impact of serum interleukin-6 and 17 level in patients with bladder
cancer: a systematic review and meta-analysis.
PeerJ. 2025;13:e19385. PubMed Abstract available
Correction to: Epidemiological and toxicological risk assessments of
ortho-toluidine for bladder cancer.
J Occup Health. 2025;67:uiaf024. PubMed
ANGELONI M, Wach S, Taubert H, Sikic D, et al Robust consensus molecular subtyping of muscle-invasive bladder cancer via 3' RNA
sequencing of FFPE tissues: potential impact for clinical and trial settings.
Lab Invest. 2025 May 2:104191. doi: 10.1016/j.labinv.2025.104191. PubMed Abstract available
LIU Z, Mao X, Xie Y, Yan Y, et al Single-cell RNA sequencing reveals a fibroblast gene signature that promotes
T-cell infiltration in muscle-invasive bladder cancer.
Commun Biol. 2025;8:696. PubMed Abstract available
CHEN R, Li Y, Zuo L, Xiong H, et al Astragalus polysaccharides inhibits tumor proliferation and enhances cisplatin
sensitivity in bladder cancer by regulating the PI3K/AKT/FoxO1 axis.
Int J Biol Macromol. 2025;311. PubMed Abstract available
CAO J, Chen S, Wang J, Fan X, et al Integrating analysis of multi-omics summary data identifies novel plasma protein
biomarkers and drug targets for bladder cancer.
Discov Oncol. 2025;16:660. PubMed Abstract available
WANG J, Wang K, Zhang J, Wu Y, et al Development of a CT radiomics model for detection of bladder invasion by
colorectal carcinoma.
Sci Rep. 2025;15:15389. PubMed Abstract available
WANG H, Zhao Y, Feng S, Wei G, et al Impact of marriage on diagnosis and survival in patients with urological cancers.
Sci Rep. 2025;15:15443. PubMed Abstract available
CAVANAUGH D, Holt SK, Dwyer E, Petersen E, et al Prospective evaluation of comprehensive geriatric assessments in
multidisciplinary bladder cancer care and implications for personalized
vulnerability phenotyping.
Urol Oncol. 2025 May 1:S1078-1439(25)00123-1. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
KJAER A, Kristjansdottir N, Juul RI, Nordentoft I, et al Low T cell diversity associates with poor outcome in bladder cancer: A
comprehensive longitudinal analysis of the T cell receptor repertoire.
Cell Rep Med. 2025 Apr 29:102101. doi: 10.1016/j.xcrm.2025.102101. PubMed Abstract available
DOGAN MB, Gunduz N, Kazan HO, Cakici MC, et al Contribution of lesion shape features to the VI-RADS for predicting muscle
invasion in bladder tumors.
Eur J Radiol. 2025;187:112104. PubMed Abstract available
LASZKIEWICZ J, Del Giudice F, Li S, Krajewski W, et al Novel risk factors for venous thromboembolism following outpatient or inpatient
transurethral resection of bladder tumors: Multivariable stepwise and LASSO
regression modeling from us insurance claim database.
Actas Urol Esp (Engl Ed). 2025;49:501738. PubMed Abstract available
CIMADAMORE A, Moschini M, Teoh J, Albisinni S, et al Real-life perception of pathology reports in urology.
Actas Urol Esp (Engl Ed). 2025;49:501751. PubMed Abstract available
TAKAHASHI T Evaluating the cost-effectiveness and evidence base for perioperative
chemotherapy in muscle-invasive bladder cancer.
World J Urol. 2025;43:310. PubMed
AZILGAREEVA K R, Morozov A O, Taratkin M S, Gazimiev M A, et al [En bloc resection of the large bladder tumors].
Urologiia. 2025;:136-140. PubMed Abstract available
NAVRIYA S, Talwar HS, Mittal A, Kumar S, et al Evidence versus practice involving universal acceptance of neoadjuvant
chemotherapy in muscle-invasive bladder cancer: Results from a tertiary care
center in India.
Indian J Cancer. 2025;62:111-119. PubMed Abstract available
ABOYAN I A, Pakus D I, Pakus S M, Shiranov K A, et al [A clinical case of bladder metastasis of skin melanoma].
Urologiia. 2024;:118-121. PubMed Abstract available
WATANABE H, Matsushita Y, Tamura K, Motoyama D, et al Robot-Assisted Radical Cystectomy With Intracorporeal Ileal Conduit Using the
Hinotori Surgical Robot System: A Single Surgeon's Initial Experience of 20
Cases.
Int J Med Robot. 2025;21:e70074. PubMed Abstract available
ZHANG R, Ke CX Advances in bladder preservation therapy for muscle-invasive bladder cancer.
Front Oncol. 2025;15:1562260. PubMed Abstract available
CHEN Y, Yan Z, Li L, Liang Y, et al Identification and validation of a 9-RBPs-related gene signature associated with
prognosis and immune infiltration in bladder cancer based on bioinformatics
analysis and machine learning.
Transl Androl Urol. 2025;14:1066-1081. PubMed Abstract available
SAHIN S, Ulus I, Canitez IO, Yentur S, et al The effect of intravesical Bacillus Calmette-Guerin (BCG) treatment on sperm
parameters in non-muscle-invasive bladder cancer patients.
Basic Clin Androl. 2025;35:17. PubMed Abstract available
YOUSAF H, Javed A, Sultana N, Farouk K, et al Corrigendum to "Unlocking the secrets: Exploring the connection between HPV and
bladder cancer in Pakistan" [Urologic Oncology: Seminars and Original
Investigations, In Press, Corrected Proof].
Urol Oncol. 2025 May 14:S1078-1439(25)00171. PubMed
WU GF, Luo ZG, Gao K, Ren Y, et al LRP8 Regulates Lipid Metabolism to Stimulate Malignant Progression and Cisplatin
Resistance in Bladder Cancer.
Kaohsiung J Med Sci. 2025 May 15:e70042. doi: 10.1002/kjm2.70042. PubMed Abstract available
LUO P, Zheng L, Zou J, Chen T, et al Corrigendum: Insights into vitamin A in bladder cancer, lack of attention to gut
microbiota?
Front Immunol. 2025;16:1609154. PubMed Abstract available
WANG Y, He M, Li J, Li L, et al Immunotherapeutic strategies for invasive bladder cancer: a comprehensive review.
Front Immunol. 2025;16:1591379. PubMed Abstract available
LI XD, Zhu JM, You Q, Wu XH, et al Identification of Selected Genes Associated With the Prediction of Prognosis in
Bladder Cancer.
Comb Chem High Throughput Screen. 2025. PubMed Abstract available
LEE HW, Jung EH, Kim KH, Ha HK, et al Real-world Efficacy of Intravesical Gemcitabine for BCG-Unresponsive
Non-Muscle-Invasive Bladder Cancer.
Cancer Res Treat. 2025 May 12. doi: 10.4143/crt.2025. PubMed Abstract available
YANG R, Wang S, Li Z, Yin C, et al Patient-derived organoid co-culture systems as next-generation models for bladder
cancer stem cell research.
Cancer Lett. 2025 May 12:217793. doi: 10.1016/j.canlet.2025.217793. PubMed Abstract available
WANG N, Song W, Ji J, Guo W, et al Metal-organic framework nanomaterials alter cellular metabolism in bladder
cancer.
Ecotoxicol Environ Saf. 2025;298:118292. PubMed Abstract available
RADU CG, Radavoi GD, Aurelian J, Achim IF, et al Quality of Life Analysis in Patients with Simple Cutaneous Ureterostomy versus
Ileal Conduit Bricker Following Radical Cystectomy.
Chirurgia (Bucur). 2025;120:205-217. PubMed Abstract available
MAO X, Yang R, Yan Y, Zeng Y, et al Single-cell analysis reveals potential therapeutic markers of peripheral blood
mononuclear cells from bladder cancer patients.
Braz J Med Biol Res. 2025;58:e14002. PubMed Abstract available
TOMIYAMA E, Fujita K, Matsuzaki K, Narumi R, et al EIF2S1 in Urinary Extracellular Vesicles as a Novel Diagnostic Marker for Bladder
Cancer.
Cancer Med. 2025;14:e70964. PubMed Abstract available
MULUK SL, Drake C, Sun Z, Bhattacharya M, et al Drive Time to Physicians and Outcomes for Bladder Cancer.
JU Open Plus. 2025;3:e00033. PubMed Abstract available
CHRYSANTHOPOULOU SA, Hedspeth T, Antinozzi D, Huang AW, et al Simulation Models for Bladder Cancer: A Scoping Review.
medRxiv [Preprint]. 2025 Mar 18:2025.03.17.25324125. PubMed Abstract available
MA Q, Hou S, Ma H, Gao J, et al Prognostic significance of circulating tumor DNA in urothelial carcinoma patients
undergoing immune checkpoint inhibitor therapy: a systematic review and
meta-analysis.
Front Immunol. 2025;16:1574449. PubMed Abstract available
KIM M, Jung E, Song G, Joung J, et al Diagnostic and Prognostic Potential of SH3YL1 and NOX4 in Muscle-Invasive Bladder
Cancer.
Int J Mol Sci. 2025;26:3959. PubMed Abstract available
DEL GIUDICE F, Abu-Ghanem Y, Nair R, Mensah E, et al Contemporary Trends and Predictors Associated with Adverse Pathological Upstaging
Among Non-Metastatic Localized Clinical T2 Muscle-Invasive Bladder Cancers
Undergoing Radical Cystectomy: Outcomes from a Single Tertiary Centre in the
United Kingdom.
Cancers (Basel). 2025;17:1477. PubMed Abstract available
CHAUDHARY P, Singha B, Abdel-Hafiz HA, Velegraki M, et al Sex differences in bladder cancer: understanding biological and clinical
implications.
Biol Sex Differ. 2025;16:31. PubMed Abstract available
LIOU K, Wang JP Integrating genetic and gene expression data in network-based stratification
analysis of cancers.
BMC Bioinformatics. 2025;26:126. PubMed Abstract available
WANG M, Chen X, Tan P, Wang Y, et al Acquired semi-squamatization during chemotherapy suggests differentiation as a
therapeutic strategy for bladder cancer.
Cancer Cell. 2025;43:985-987. PubMed
DENG J, Wang G, Yang Y, Liao M, et al A rare case report: Bladder endometriosis at the urachus.
J Int Med Res. 2025;53:3000605251340535. PubMed Abstract available
YE J, Xie Y, Ran B, Han P, et al Prognostic impact of nutritional indicators based on Lasso-Cox regression for
non-muscle-invasive bladder cancer.
Front Nutr. 2025;12:1560655. PubMed Abstract available
FRASLIN A, Colrat F, Karimi M, Bonastre J, et al Characteristics, management and survival outcomes in patients with
muscle-invasive bladder cancer at high risk of recurrence in France: a subgroup
analysis from the coblance cohort.
BMC Urol. 2025;25:120. PubMed Abstract available
ROA FJ, Roubelakis M, Paschidis K, van Creij NCH, et al Repurposing amiodarone for bladder cancer treatment.
Cancer Res Commun. 2025 May 12. doi: 10.1158/2767-9764.CRC-24-0433. PubMed Abstract available
NAKATAKE N, Ueda N, Takezawa K, Kato T, et al [A Case of Open Poucholithotomy for Recurrence of Indiana Pouch Stones].
Hinyokika Kiyo. 2025;71:115-119. PubMed Abstract available
IKADAI R, Arase S, Hasegawa Y [Nephrogenic Adenoma : A Case Report].
Hinyokika Kiyo. 2025;71:111-113. PubMed Abstract available
LIU C, Liao C, Sun B, Guo Z, et al Tumour-infiltrating immune cells as a novel prognostic model for bladder cancer.
Discov Oncol. 2025;16:725. PubMed Abstract available
LIMA MZT, Bastos DA, Mattedi RL, Dzik C, et al Infiltrating Natural Killer cells influence the efficacy of BCG immunotherapy in
non-muscle-invasive bladder cancer.
Pathol Res Pract. 2025;270:155997. PubMed Abstract available
OSKOUIE IM, Amirzargar H, Dezfuli AS, Mashhadi R, et al Reducing the effective dosage of Mitomycin C on a high-grade bladder cancer cell
line through combination with selenium nanoparticles: An in vitro study.
Med Oncol. 2025;42:207. PubMed Abstract available
ZHAO K, Xu G, Jin J, Peng C, et al Integrated prognostic assessment of apoptosis and chemotherapy related gene in
bladder cancer: a prognostic signature.
Discov Oncol. 2025;16:718. PubMed Abstract available
LI W, Yin Q, Qiu Y, Liu J, et al Mechanistic study of Liquiritigenin inhibiting bladder cancer cell proliferation
and migration by regulating STING1.
Cancer Genet. 2025;294-295:156-170. PubMed Abstract available
SAZUKA T, Taoka R, Miki J, Saito R, et al Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive
bladder cancer: Japanese multicenter retrospective study.
Int J Clin Oncol. 2025 May 10. doi: 10.1007/s10147-025-02778. PubMed Abstract available
KUMAR S, Mehta R, Sah R Letter: Comment on "Enhanced Artificial Intelligence in Bladder Cancer
Management: A Comparative Analysis and Optimization Study of Multiple Large
Language Models".
J Endourol. 2025 May 9. doi: 10.1089/end.2025.0277. PubMed
LIU H, Ma J, Yan X Circ_RPPH1 promotes bladder urothelium carcinoma proliferation and EMT by
recruiting and binding to EIF4 A3.
Hereditas. 2025;162:72. PubMed Abstract available
SHI K, Li X, Chen R, Wang Z, et al Bousigonine D from Bousigonia mekongensis inhibits bladder cancer growth and
overcomes cisplatin resistance.
Sci Rep. 2025;15:16254. PubMed Abstract available
ZHU J, Zhu Y, Huang J, Zhang W, et al Icing on the Cake: Integrating Optical Fiber with Second Near-Infrared
Aggregation-Induced Emission Luminogen for Exceptional Phototheranostics of
Bladder Cancer.
Adv Mater. 2025 May 9:e2502452. doi: 10.1002/adma.202502452. PubMed Abstract available
MACDONALD L, Smith M, Bree KK New Paradigms for Bladder Cancer Management in Geriatrics.
Clin Geriatr Med. 2025;41:175-185. PubMed Abstract available
MIKOLASKOVA I, Gidron Y, Durmanova V, Suchankova M, et al Mental distress and inflammation in bladder cancer: The nerve makes things less
vague.
Brain Behav Immun Health. 2025;46:100995. PubMed Abstract available
KHAN AA, Ahluwalia C, Khurana R, Ahuja S, et al Evaluation of the EMT Markers SNAIL-SLUG and TWIST in Urothelial Carcinoma of the
Bladder: A Retrospective Study.
Arch Esp Urol. 2025;78:289-295. PubMed Abstract available
AL-NADER M, Krafft U, Darr C, Hess J, et al Impact of Extended Versus Limited Lymph Node Dissection on Surgical Outcome,
Recurrence Patterns and Survival After Radical Cystectomy.
Clin Genitourin Cancer. 2025;23:102337. PubMed Abstract available
BARIS MOGUL C, Duran MB, Caner V, Turk NS, et al The PD-L1 Promoter Methylation Predicts Gene And Protein Expression Levels in
Urothelial Carcinoma.
Gene. 2025;959:149503. PubMed Abstract available
GEYNISMAN DM, Chepynoga K, Yates G, Tate A, et al Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term
Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial
Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase
3 CheckMate 274 Trial
Clin Genitourin Cancer. 2025;23:102335. PubMed Abstract available
GUAN B, Chen S, Tao Z, Jiang Y, et al Pattern and risk factors of local recurrence and intravesical recurrence after
segmental ureterectomy for upper tract urothelial carcinoma.
Urol Oncol. 2025;43:330. PubMed Abstract available
MIYAKE M, Nishimura N, Iemura Y, Yoshikawa M, et al Impact of Initial Relative Dose Intensity on Tumor Response and Survival Outcomes
in Enfortumab Vedotin Monotherapy for Previously Treated Advanced Urothelial
Carcinoma: A Real-world Analysis From a Multicenter Study.
Clin Genitourin Cancer. 2025;23:102326. PubMed Abstract available
REESINK DJ, Voskuilen CS, van de Garde EMW, Hendricksen K, et al Survival in Responders and Nonresponders of Neoadjuvant and Induction
Chemotherapy in Invasive Urothelial Carcinoma of the Urinary Bladder: A Clinical
and Pathological Stage-Matched Analysis.
Clin Genitourin Cancer. 2025;23:102319. PubMed Abstract available
KUERBITZ EM, Dhawan D, Utturkar S, Sola MF, et al Characterisation of Gene Expression in Canine Invasive Urothelial Carcinoma Using
a NanoString-Based Urine Assay.
Vet Comp Oncol. 2025;23:205-215. PubMed Abstract available
SANTONI M, Rizzo A, Massari F Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab
vedotin in patients with urothelial carcinoma.
Expert Opin Investig Drugs. 2025;34:259-265. PubMed Abstract available
LIU Y, Jia C, Wang Z, Zhang Y, et al Temozolomide as neoadjuvant therapy for bladder paraganglioma.
Endocrine. 2025;88:431-433. PubMed Abstract available
KUMAR S, Nayyar R, Jain S, Seth A, et al Immediate second resection versus restage transurethral resection of bladder
tumor: A prospective randomized clinical trial (IMMERSE trial).
Urol Oncol. 2025;43:331. PubMed Abstract available
MAKLIN T, Taira A, Arredondo-Alonso S, Shao Y, et al Geographical variation in the incidence of colorectal cancer and urinary tract
cancer is associated with population exposure to colibactin-producing Escherichia
coli.
Lancet Microbe. 2025;6:101015. PubMed Abstract available
ZENG E, Saucke M, Rose A, Pati B, et al "I was in a very deep, dark place... I wasn't prepared for that": A qualitative
assessment of the emotional well-being needs of patients undergoing cystectomy.
Urol Oncol. 2025;43:328. PubMed Abstract available
KIR G, Cecikoglu GE, Aydin A, Yildirim A, et al The clinical relevance of cut-off percentage for high-grade urothelial carcinoma
within low-grade urothelial carcinoma: A determining factor?
Urol Oncol. 2025;43:329. PubMed Abstract available
SIEFKER-RADTKE AO, Huddart RA, Bilen MA, Balar A, et al Bempegaldesleukin plus nivolumab in first-line advanced/metastatic urothelial
carcinoma: Results from a phase II single-arm study (PIVOT-10).
Urol Oncol. 2025;43:330. PubMed Abstract available
KLUMPER N, Cox A, Sjodahl G, Roghmann F, et al Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial
cancer.
Nat Rev Urol. 2025;22:256-267. PubMed Abstract available
YASUOKA S, Minegishi T, Kojima S, Okuyama K, et al Real-world treatment patterns and outcomes of patients with unresectable or
metastatic urothelial carcinoma receiving systemic therapy in Japan.
Urol Oncol. 2025;43:329. PubMed Abstract available
HINOJOSA-GONZALEZ DE, Saffati G, Wahlstedt E, Chaput M, et al Oncologic outcomes of pelvic organ-preserving radical cystectomy vs. Standard
radical cystectomy: A systematic review and meta-analysis.
Urol Oncol. 2025;43:275-285. PubMed Abstract available
DOS REIS PF, Martucci RB Factors influencing health-related quality of life in patients with bladder or
kidney cancer: a prospective cohort study of the impact of nutritional status and
frailty phenotype.
J Cancer Surviv. 2025;19:743-753. PubMed Abstract available
DE ANGELIS M, Baudo A, Siech C, Jannello LMI, et al The effect of race/ethnicity on cancer-specific mortality after trimodal therapy.
J Racial Ethn Health Disparities. 2025;12:1416-1422. PubMed Abstract available
WEI FY, He QH, Yin BT, Zhao JW, et al Circulating metabolic biomarkers mediated causal relationship between gut
microbiota and bladder cancer: a two-step mendelian randomization study.
Discov Oncol. 2025;16:877. PubMed Abstract available
CAI L, Zhang S, Zheng F, Ji F, et al Identification of SCAMP2 as a regulator of NOTCH signaling in cisplatin
resistance through a novel prognostic model for bladder cancer.
Front Immunol. 2025;16:1573412. PubMed Abstract available
HAN X, Chen H, Wang B Efficacy of brachytherapy for locally advanced bladder cancer: a single-center
retrospective clinical study.
Cancer Biol Ther. 2025;26:2509200. PubMed Abstract available
WU Q, Yu H, Sun H, Lv J, et al SRSF1-mediated alternative splicing regulates bladder cancer progression and
cisplatin sensitivity through HIF1A/BNIP3/mitophagy axis.
J Transl Med. 2025;23:571. PubMed Abstract available
SHU Z, Liu X, Li X, Fu S, et al RAP1GAP is a prognostic biomarker and correlates with immune infiltrates in
bladder cancer.
Discov Oncol. 2025;16:863. PubMed Abstract available
BOURGI A, Vincentelli A, Rusch E, Bruyere F, et al Youth matters: a systematic review of the molecular and clinical landscape of
bladder cancer in young adults.
World J Urol. 2025;43:321. PubMed Abstract available
LIU Z, Xin P, Wu W, Jin M, et al Nanoparticle-mediated targeting of PGC-1alpha reveals critical metabolic pathways in
bladder cancer metastasis.
Commun Biol. 2025;8:788. PubMed Abstract available
RODRIGUEZ PENARANDA N, de Angelis M, Siech C, Di Bello F, et al Perioperative Complications and In-hospital Mortality After Cystectomy for
Nonbladder Cancer Conditions Versus Radical Cystectomy for Bladder Cancer.
Ann Surg Oncol. 2025 May 22. doi: 10.1245/s10434-025-17456. PubMed Abstract available
CHEN R, Ye Y, Zheng Y Establishment of a m6 A-associated lncRNAs-derived risk model for enhanced
patient prognosis stratification and personalized therapy approaches in bladder
cancer.
Discov Oncol. 2025;16:856. PubMed Abstract available
WANG C, Shu Y, Shan J, Li K, et al Discovery and Validation of a New Biomarker Integrating Ferroptosis and
Glycolysis-Related Genes in Bladder Cancer.
IUBMB Life. 2025;77:e70028. PubMed Abstract available
CIGLIOLA A, Tateo V, Michela R, Di Maria G, et al Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting
nectin-4 for the treatment of bladder cancer.
Expert Opin Investig Drugs. 2025 May 22. doi: 10.1080/13543784.2025.2510669. PubMed Abstract available
HUYNH TNA, Arulshankar S, Wei X, Lim KY, et al Insights Into Rural Chemotherapy Usage for Muscle-Invasive Bladder Cancer: An
Australian Multi-Site Institution Perspective.
ANZ J Surg. 2025 May 22. doi: 10.1111/ans.70175. PubMed
MIRZAEI A, Taheri D, Fattahi B, Alaeddini F, et al SPP1A and VEGFC splice isoforms as predictive diagnostic biomarkers for high and
low-grade bladder cancer.
Am J Clin Exp Urol. 2025;13:156-168. PubMed Abstract available
KILIC S, Sugur T, Metinyurt HF, Demir Y, et al Open radical cystectomy and ileal loop diversion under combined spinal-epidural
anaesthesia for the elderly and frail.
BMC Surg. 2025;25:222. PubMed Abstract available
DING X, Liu C, Li X, Wang Z, et al Real-world comparison of neoadjuvant chemoimmunotherapy and chemotherapy in
muscle-invasive bladder cancer.
Sci Rep. 2025;15:17588. PubMed Abstract available
CONTIERI R, Martini A, Beijert IJ, Mertens LS, et al Towards Defining Follow-up Strategies for Patients with Primary Intermediate-risk
Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 May 20:S2588-9311(25)00104. PubMed Abstract available
REJEB SB, Kouki N, Khouni H, Boulma R, et al Prognostic Significance of Regulatory CD25+ T Cells in Bladder Cancer: An
Immunohistochemical Analysis.
Turk Patoloji Derg. 2025;1. PubMed Abstract available
WANG B, Weight C, Calaway A, Abouassaly R, et al Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive
non-muscle-invasive bladder cancer, a study with 5-year follow-up: a plain
language summary.
Future Oncol. 2025 May 21:1-11. doi: 10.1080/14796694.2025.2493041. PubMed
TENG X, Chen Z, Bai Y, Cao H, et al Tertiary Lymphoid Structures as Independent Predictors of Favorable Prognosis in
Muscle-Invasive Bladder Cancer.
Cancer Med. 2025;14:e70978. PubMed Abstract available
HUANG K, Yang C, Xu Y, Wang Y, et al Unraveling the multifaceted roles of extracellular vesicles in bladder cancer:
diagnostic insights and therapeutic opportunities.
Front Oncol. 2025;15:1554819. PubMed Abstract available
LY TM, Bui HMH, Bui PT, Ly N, et al Small bowel obstruction from urachal cyst abscess: a diagnostic challenge easily
confused with invasive urachal cancer-A case report.
J Med Case Rep. 2025;19:240. PubMed Abstract available
YUAN Y, Liu T, Yao Y, Ma Q, et al Metabolic syndrome and bladder cancer risk: a comprehensive evidence synthesis
combining bibliometric and meta-analysis approaches.
BMC Urol. 2025;25:132. PubMed Abstract available
SCILIPOTI P, Longoni M, de Angelis M, Zaurito P, et al Long-term Oncological Outcomes for Patients with Non-muscle-invasive Bladder
Cancer Treated with Bacillus Calmette-Guerin (BCG): A Comparative Analysis of
Adequate Versus Inadequate BCG Treatment.
Eur Urol Focus. 2025 May 19:S2405-4569(25)00111. PubMed Abstract available
ERAKY A, Ben-David R, Hug B, Kolanukuduru KP, et al Bladder Cancer with Undetectable Circulating Tumor DNA After Radical Cystectomy
May Be Amenable to a Less Intense Imaging Surveillance Protocol: A Diagnostic
Accuracy Study.
Eur Urol Oncol. 2025 May 19:S2588-9311(25)00124. PubMed Abstract available
CHEN C, Wu Y, Wu J, Sun R, et al Identification of a panel of lncRNAs derived from urinary extracellular vesicles
as non-invasive diagnostic biomarkers for bladder cancer.
Clin Chim Acta. 2025 May 18:120376. doi: 10.1016/j.cca.2025.120376. PubMed Abstract available
RIBAL MJ, Rosenberg J, Ajami T, Vilaseca A, et al Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder
Cancer: A Step Forward.
Am Soc Clin Oncol Educ Book. 2025;45:e472822. PubMed Abstract available
HINOJOSA-GONZALEZ DE, Saffati G, La T, Cathey J, et al Comparative effectiveness of en-bloc resection techniques vs. conventional
transurethral resection for non-muscle-invasive bladder cancer: A systematic
review and meta-analysis.
Can Urol Assoc J. 2025 May 16. doi: 10.5489/cuaj.9070. PubMed Abstract available
LI X, Zou C, Wang C, Chang C, et al Non-Invasive Tumor Budding Evaluation and Correlation with Treatment Response in
Bladder Cancer: A Multi-Center Cohort Study.
Adv Sci (Weinh). 2025 May 20:e2416161. doi: 10.1002/advs.202416161. PubMed Abstract available
CHENG H, Li Y, Shen S Determination of Nitrogen Metabolism-Related Prognostic Signatures for
Forecasting Bladder Cancer Prognosis.
Endocr Metab Immune Disord Drug Targets. 2025. PubMed Abstract available
YAMASHITA R, Sugino T, Notsu A, Nakaya Y, et al Relationship between urinary pH and efficacy of Bacillus Calmette-Guerin
treatment in patients with carcinoma in situ of the bladder.
World J Urol. 2025;43:317. PubMed Abstract available
MAO M, Zhang Y, Liu H, Jiang X, et al Identification of a panel of volatile organic compounds in urine for early
detection of for bladder cancer.
Sci Rep. 2025;15:17383. PubMed Abstract available
CHEN J, Wang W, Li M, Pan S, et al Advances in the diagnosis and treatment of urethral metastasis after urothelial
carcinoma surgery: A case series and literature review of 3 total ureterectomy
cases.
Medicine (Baltimore). 2025;104:e42329. PubMed Abstract available
JOCK Q, Levi LI, Lafaurie M, Goujon A, et al Organizational impact of systematic urine culture before Bacillus Calmette Guerin
(BCG) induction instillations.
World J Urol. 2025;43:316. PubMed Abstract available
GHANDOUR Y, AlJardali B, Sebai T, Zein M, et al Can ureteral stents be omitted from radical cystectomy with continent diversion?
An ACS-NSQIP analysis of the early postoperative outcomes.
World J Urol. 2025;43:314. PubMed Abstract available
HASAN N, Yang D, Gibson S, Khaleghi B, et al Advancements in bladder cancer treatment: The synergy of radiation and
immunotherapy.
Oncotarget. 2025;16:337-346. PubMed Abstract available
LIU Z, Jia B, Zhai Z, Wu F, et al AP1M2 Drives Gemcitabine-Cisplatin Chemoresistance by Enhancing RAD54B-Associated
DNA Repair in Bladder Cancer.
FASEB J. 2025;39:e70595. PubMed Abstract available
AGARWAL M, Kumar Panwar V, Mittal A, Dev D, et al Changing Clinical Spectrum and Disease Progression in Young Patients With Bladder
Cancer: A Retrospective Observational Study.
Cureus. 2025;17:e82516. PubMed Abstract available
BENTO I, Freitas J, Campos B, Fonseca T, et al Behind the Smoke: A Bladder Cancer Case Report Through the Eyes of Primary Care.
Cureus. 2025;17:e82435. PubMed Abstract available
WANG R, Zhao C, Ou Z, Chen L, et al KHSRP promotes the malignant behavior and cisplatin resistance of bladder cancer
cells through the CLASP2/MAPRE1 axis.
Pharmacogenomics J. 2025;25:14. PubMed Abstract available
BERTRAND A, Roumeguere T, Vandamme J, Spinoit AF, et al National Belgian survey on managing non-muscle invasive bladder cancer during
Mitomycin and bacillus Calmette-Guerin shortage.
Fr J Urol. 2025 May 15:102905. doi: 10.1016/j.fjurol.2025.102905. PubMed Abstract available
SHANG H, Xia D, Geng R, Wu J, et al Thermosensitive Resiquimod-Loaded Lipid Nanoparticles Promote the Polarization of
Tumor-Associated Macrophages to Enhance Bladder Cancer Immunotherapy.
ACS Nano. 2025 May 17. doi: 10.1021/acsnano.4c17444. PubMed Abstract available
WANG K, Zhang M, Huang C, Zhang J, et al Photo-Activated PROTACs for Targeted BRD4 Degradation and Synergistic
Photodynamic Therapy in Bladder Cancer.
Mol Pharm. 2025 May 17. doi: 10.1021/acs.molpharmaceut.5c00271. PubMed Abstract available
QIAO Y, Zhao W, Gou Y, Li Y, et al Research hotspots and frontier analysis of the novel immune checkpoint Nectin-4.
Hum Vaccin Immunother. 2025;21:2504776. PubMed Abstract available
MOU Y, Liu Z, Xu W, Zheng B, et al Dual-source powered sea urchin-like nanomotors for intravesical photothermal
therapy of bladder cancer.
J Nanobiotechnology. 2025;23:355. PubMed Abstract available
PU Q, Gao F, Xiao Y, Wu J, et al Tobacco smoking exposure-mediated ELAVL1 regulates bladder cancer cell senescence
via autophagy activation.
Toxicology. 2025;516:154193. PubMed Abstract available
SUN J, Chu R, Wu X, Yu Q, et al Anti-biopassivated Reticular Micromotors for Bladder Cancer Therapy.
J Am Chem Soc. 2025 May 16. doi: 10.1021/jacs.5c02949. PubMed Abstract available
SONG X, Yu X, Moran-Segura CM, Xu H, et al ROICellTrack: a deep learning framework for integrating cellular imaging
modalities in subcellular spatial transcriptomic profiling of tumor tissues.
Bioinformatics. 2025;41:btaf152. PubMed Abstract available
TRECARTEN S, Schaefer C, Elshabrawy A, Abdelaziz A, et al Two-year resource utilization of open vs. robot-assisted radical cystectomy:
Results from optum's de-identified clinformatics(R) data mart database.
Urol Oncol. 2025;43:391. PubMed Abstract available
AUNG YK, Zhang Y, Jenkins MA, Win AK, et al Risks of colorectal and extracolonic cancers following colorectal cancer: a
systematic review and meta-analysis.
JNCI Cancer Spectr. 2025;9:pkaf031. PubMed Abstract available
RICH JM, Tillu N, Geduldig J, Ben-David R, et al Contemporary outcomes for robotic radical cystectomy and intracorporeal
neobladder urinary diversion.
Urol Oncol. 2025;43:392. PubMed Abstract available
RICCIARDI G, Fiorentino V, Pierconti F, Giordano WG, et al Roles for Androgen Receptor, ADAR2, and PD-L1 in Primary Urothelial Carcinoma In
Situ of the Bladder Treated with Bacillus Calmette-Guerin Therapy.
Lab Invest. 2025;105:104120. PubMed Abstract available
RUSSO P, Foschi N, Palermo G, Maioriello G, et al SIRI as a biomarker for bladder neoplasm: Utilizing decision curve analysis to
evaluate clinical net benefit.
Urol Oncol. 2025;43:393. PubMed Abstract available
TANIA C, Sihombing AT, Siregar S Comparison of direct oral anticoagulant (DOAC) versus low-molecular-weight
heparin (LMWH) for venous thromboprophylaxis after radical cystectomy: A
systematic review and meta-analysis.
Urol Oncol. 2025;43:341-347. PubMed Abstract available
FURUBAYASHI N, Mochida M, Kijima A, Fujimoto Y, et al Treatment Outcomes After Progression With Enfortumab Vedotin in Patients With
Advanced Urothelial Carcinoma.
Anticancer Res. 2025;45:2185-2193. PubMed Abstract available
TUNG CH, Lin SH, Chang KP, Xu YW, et al Light Bladder Net: Non-invasive Bladder Cancer Prediction by Weighted Deep
Learning Approaches and Graphical Data Transformation.
Anticancer Res. 2025;45:1953-1964. PubMed Abstract available
HANEY CM, Studier-Fischer A, Geissler ME, Ohlmeier J, et al Indocyanine-guided ureter resection for radical cystectomy - a systematic review
and meta-analysis.
BJU Int. 2025;135:908-917. PubMed Abstract available
AMPARORE D, De Cillis S, Colombo M, Garzena V, et al TYTOCARE home telemonitoring device after radical cystectomy to optimise
postoperative outcomes.
BJU Int. 2025;135:960-968. PubMed Abstract available
VAN HATTUM JW, Remmelink MJ, Nuijens ST, de Ruiter BM, et al A study of oral metformin for the intravesical treatment of non-muscle-invasive
bladder cancer.
BJU Int. 2025 May 22. doi: 10.1111/bju.16767. PubMed Abstract available
LONGONI M, Scilipoti P, De Angelis M, Zaurito P, et al Contemporary outcomes in non-muscle-invasive bladder cancer: a large European
multicentre study.
BJU Int. 2025 May 21. doi: 10.1111/bju.16780. PubMed Abstract available
RODRIGUEZ-MORENO JF, de Velasco G, Alvarez-Fernandez C, Collado R, et al Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib
in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
Clin Cancer Res. 2025;31:1644-1656. PubMed Abstract available
ALFRED WITJES J Follow-up for Non-muscle-invasive Bladder Cancer: Should the Guidelines Be
Adapted?
Eur Urol. 2025 Apr 25:S0302-2838(25)00218-0. doi: 10.1016/j.eururo.2025. PubMed
PANEBIANCO V, Briganti A, Efstathiou J, Galgano S, et al Reply to Francesco Montorsi, Giuseppe Rosiello, Pietro Scilipoti, Marco Moschini,
and Andrea Salonia's Letter to the Editor re: Valeria Panebianco, Alberto
Briganti, Jason Efstathiou, et al. The Role of Multiparametric Magnetic Resonance
Imaging and t
Eur Urol. 2025 Apr 24:S0302-2838(25)00199-X. doi: 10.1016/j.eururo.2025. PubMed
DREYER T, Brandt S, Fabrin K, Azawi N, et al Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding
Cystoscopy in High-grade Non-muscle-invasive Bladder Cancer: Results from the
Randomized Controlled DaBlaCa-15 Trial.
Eur Urol. 2025 Apr 24:S0302-2838(25)00191-5. doi: 10.1016/j.eururo.2025. PubMed Abstract available
ZAURITO P, Moschini M, Briganti A, Montorsi F, et al Re: Douglas M. Dahl, Joseph P. Rodgers, William U. Shipley, et al.
Bladder-preserving Trimodality Treatment for High-grade T1 Bladder Cancer:
Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol
2024;42:4095-102.
Eur Urol. 2025 May 3:S0302-2838(25)00250-7. doi: 10.1016/j.eururo.2025. PubMed
SUBIELA JD, Scilipoti P, Contieri R, Lobo N, et al Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer:
Real-World Data Challenge the Guideline Recommendation for Upfront Radical
Cystectomy.
Eur Urol. 2025 May 14:S0302-2838(25)00283-0. doi: 10.1016/j.eururo.2025. PubMed Abstract available
WARD DG, Bryan RT Should We Incorporate Urinary Tumour DNA Status in Treatment Decisions for
Patients with Non-muscle-invasive Bladder Cancer?
Eur Urol. 2025 May 10:S0302-2838(25)00268-4. doi: 10.1016/j.eururo.2025. PubMed
ST-LAURENT MP, Singh P, McConkey DJ, Lucia MS, et al Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with
Atezolizumab for Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive
Bladder Cancer.
Eur Urol. 2025 May 21:S0302-2838(25)00217-9. doi: 10.1016/j.eururo.2025. PubMed Abstract available
FANKHAUSER CD, Cathomas R Re: Randomized Comparison of Magnetic Resonance Imaging Versus Transurethral
Resection for Staging New Bladder Cancers: Results from the Prospective
BladderPath Trial.
Eur Urol. 2025 May 19:S0302-2838(25)00290-8. doi: 10.1016/j.eururo.2025. PubMed
SCHOFIELD E, Catto JWF, Griffin J Subtypes and Sequencing in Bladder Cancer: Powering Personalised Treatment or
Extraneous Information?
Eur Urol. 2025 May 16:S0302-2838(25)00277-5. doi: 10.1016/j.eururo.2025. PubMed
CHEN J, Xiao S, Yan X, Wei Y, et al Mechanism of SMYD2 promoting stemness maintenance of bladder cancer stem cells by
regulating PYCR1 expression and PINK1/Parkin mitophagy pathway.
Int J Oncol. 2025;66:41. PubMed Abstract available
YONEYAMA F, Shinohara M, Kawashima Y, Yoneyama A, et al Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and
Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter
Retrospective Study.
Int J Urol. 2025 May 1. doi: 10.1111/iju.70087. PubMed Abstract available
KOBATAKE K, Goto K, Sakamoto Y, Iwane K, et al Influence of best objective response to first-line treatment on survival outcomes
in advanced urothelial carcinoma in the era of sequential therapy with enfortumab
vedotin.
Int J Urol. 2025;32:524-530. PubMed Abstract available
KANNO T, Ito K, Kita Y, Mochizuki T, et al Impact of lymph node dissection during surgery on the efficacy of pembrolizumab
in patients with metastatic urothelial carcinoma.
Int J Urol. 2025;32:593-597. PubMed Abstract available
YAMADA Y, Taguchi M, Shimatani K, Yanagi T, et al The usefulness of transarterial embolization before transurethral resection of
bladder tumor for patients with large bladder tumors.
Int J Urol. 2025;32:488-492. PubMed Abstract available
WADA N, Hatakeyama T, Takagi H, Tsunekawa R, et al Trends in age and antithrombotic therapy in patients who underwent transurethral
resection of bladder tumor and perioperative complications.
Int J Urol. 2025;32:516-523. PubMed Abstract available
MIYAKE M Editorial Comment From Dr. Miyake to Effects of Robot-Assisted Radical Cystectomy
on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive
Bladder Cancer: A Multicenter Retrospective Study.
Int J Urol. 2025 May 15. doi: 10.1111/iju.70112. PubMed
SASAKI D, Yoneyama T, Yoneyama F, Ozaki K, et al PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in
Muscle-Invasive Bladder Cancer.
Int J Urol. 2025 May 23. doi: 10.1111/iju.70122. PubMed Abstract available
GAO S, Liu T, Liu Q DNMT1 promotes bladder cancer progression and immune escape by inhibiting MYH11
expression by methylating its promoter.
Int Urol Nephrol. 2025 May 2. doi: 10.1007/s11255-025-04527. PubMed Abstract available
LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al Oncological outcomes after non-surgical management versus radical cystectomy in
non-organ-confined non-urothelial bladder cancer.
Int Urol Nephrol. 2025 May 7. doi: 10.1007/s11255-025-04566. PubMed Abstract available
MAHRAN SE, Salem SE, Sabry NA, Farid SF, et al The nephroprotective effect of metformin with cisplatin in bladder cancer:
randomized clinical trial.
Int Urol Nephrol. 2025 May 3. doi: 10.1007/s11255-025-04505. PubMed Abstract available
MA W, Shui Y, Wang G, Zhang X, et al Previous maximal transurethral resection of bladder tumor lead to unfavorable
perioperative outcomes following radical cystectomy.
Int Urol Nephrol. 2025;57:1817-1826. PubMed Abstract available
ZHANG S, Chen C, Mo C, Fan N, et al A clinical study of RC48-ADC combined with PD-1 inhibitor in bladder preservation
therapy for muscle-invasive bladder cancer (MIBC)-based on real-world data
analysis.
Int Urol Nephrol. 2025 May 14. doi: 10.1007/s11255-025-04567. PubMed Abstract available
VENKATRAMANI V, Reis IM, Gonzalgo ML, Swain S, et al Comparison of Complication and Readmission Rates Between Robot-Assisted and Open
Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.
J Urol. 2025;213:684-692. PubMed Abstract available
HAMADA A, Kita Y, Sakatani T, Nakamura K, et al PTEN loss drives p53 LOH and immune evasion in a novel urothelial organoid model
harboring p53 missense mutations.
Oncogene. 2025;44:1336-1349. PubMed Abstract available
MUNKER KA, Reineke D, Schneidewind L, Mussgens C, et al A rare case of a plasmacytoid and sarcomatoid differentiated urothelial bladder
carcinoma with a single metastasis to the right ventricle of the heart and rapid
review of single heart metastasis in bladder cancer.
Urol Int. 2025 Apr 26:1-15. doi: 10.1159/000546149. PubMed Abstract available
LU Y, Wu H, Jiang J, Bao S, et al The value of circulating tumor DNA in the prognostic diagnosis of bladder cancer:
a systematic review and meta-analysis.
Urol Int. 2025 May 2:1-17. doi: 10.1159/000546014. PubMed Abstract available
HIGGINS MI, Li J, Ahmed W, Lu C, et al Detection Of High-Grade Bladder Cancer In Urine Samples Using In Situ
Hybridization Of Long Non-Coding RNA UCA1.
Urology. 2025 May 13:S0090-4295(25)00468-6. doi: 10.1016/j.urology.2025. PubMed Abstract available
WANG X, Qu Y, Sun Y, Yang T, et al ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT
signaling.
BMC Cancer. 2025;25:789. PubMed Abstract available
KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al Clinicopathological characteristics of transcription factor-defined subtypes in
bladder small cell carcinoma.
BMC Cancer. 2025;25:766. PubMed Abstract available
LAN T, Zhu Y, Zhong W, Tan Q, et al Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab
Vedotin combined with Toripalimab and pelvic lymph node dissection in
muscle-invasive bladder cancer patients: study protocol of a multicenter
single-arm phase II trial.
BMC Cancer. 2025;25:868. PubMed Abstract available
N S, Ps H, P R, Paul L, et al Novel Gene expression-based Risk Stratification tool predicts recurrence in
Non-muscle invasive Bladder cancer.
BMC Cancer. 2025;25:916. PubMed Abstract available
